Analysts’ Viewpoint on Albumin Market Scenario
In order to emerge resilient to the COVID-19 outbreak, companies in the global market for albumin are expected to adopt contingency planning across departments to revive organizational revenue and capital expenditure. Extraction of recombinant human serum albumin and processing incur significant cost & expertise. Additionally, it requires expert staff to handle operations, as the recombinant technology attracts stringent laws and regulations. Moreover, cost associated with refinement of recombinant albumin to attain high purity is a major concern among the industry players. This acts as a major restraint for the global market. Hence, companies should work closely with governments in developed economies of North America and Europe to employ supportive regulatory policies that help to lower the cost of albumin production. They should diversify business activities in developing economies such as India and China to capitalize on value-grab opportunities.
Geographically, North America and Europe are projected to be highly attractive markets for albumin during the forecast period. A rise in investments in life sciences by a large number of biopharmaceutical companies and research institutes is expected to boost the global market for albumin in these regions throughout the assessment period.
The demand for albumin is high in countries such as India and China. However, the uptake of these therapeutics is low due to the lack of awareness about these products and their therapeutic uses. Hence, awareness programs conducted by healthcare organizations which include International Plasma Awareness Week, to help increase awareness about plasma donation and the different plasma protein therapies available, along with their potential uses are expected to increase the demand for these therapeutics in treating various conditions.
Companies in the albumin market are maintaining optimum inventory levels to cater to mission-critical projects in the healthcare industry amid the ongoing coronavirus pandemic. Different regions of the world are showing signs that supply chains are recovering as the production & movement of goods are speeding up. Manufacturers based in the Western Hemisphere have been making significant progress in the past few years to secure themselves against volatility in supply from Asia, China in particular, by moving the bulk production to their respective countries.
Companies in the albumin market are launching chemically defined, blood and plant hydrolysate-free cell culture media for vaccine manufacturing that outperforms popular VERO media by enabling robust VERO cell expansion and production of difficult-to-express virus types.
Albumin is being widely used as a versatile drug carrier in systems such as albumin fusion protein, albumin-drug nanoparticles, and pro-drugs. It is used as a drug carrier for the treatment of various diseases such as rheumatoid arthritis, diabetes, cancer, and hepatitis.
It also has the ability to bind to an extraordinarily diverse range of molecules, as it provides a depository for various compounds. These factors make albumin most suitable to be used as an excipient in vaccine and drug production.
An increase in the usage of albumin as a multifunctional excipient, a shift toward the usage of recombinant albumin, and a grant of regulatory approvals are key factors that are driving the albumin market. However, the high cost & expertise required to set up production plants and stringent regulatory criteria are restraining the growth rate of the market. Nevertheless, emerging markets such as India, China, Brazil, and South Africa present significant opportunities in the global market, owing to growing contract research manufacturing. Such findings are helping stakeholders in the global market for albumin to diversify their business activities in regions where regulatory standards are comparatively easier to adhere to.
Technological developments in drug formulation & drug delivery and an increase in access to technologies such as the use of albumin in cell culture media present lucrative opportunities for investors. Hence, investments by manufacturers in these developing markets, an increase in contract research manufacturing, and a rise in demand & awareness among end users are expected to boost the growth of the global market.
In terms of product, the human serum albumin segment is anticipated to account for a major market share of approximately 80%, in terms of revenue, during the forecast period. The growth of the segment can be attributed to the increase in the prevalence of life-threatening disorders & conditions, especially liver diseases, infections, and cardiac surgeries leading to hypoalbuminemia. Other factors driving the segment include the rise in the adoption of albumin products and an increase in the usage of non-therapeutic applications across the world.
Based on application, drug delivery is expected to be the most attractive segment during the forecast period. Collaboration between pharmaceutical and biotechnology companies for the use of recombinant albumin-based drug delivery systems is likely to propel the growth of the segment. In terms of end-user, the pharmaceutical & biotechnology industry segment is expected to dominate the market throughout the assessment period. The segment was valued at US$ 500 Mn in 2017. The rise in research and developmental (R&D) activities for the development of technologically advanced products and an increase in government funding are attributed to the growth of the segment.
|
Attribute |
Detail |
|
Market Size Value in 2020 |
US$ 4.6 Bn |
|
Market Forecast Value in 2031 |
US$ 8.1 Bn |
|
Growth Rate (CAGR) |
6.1% |
|
Forecast Period |
2021–2031 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes cross-segment analysis at the global as well as regional levels. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, and a parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The albumin market is expected to reach the value of US$ 8.1 Bn by the end of 2031
The global market is estimated to expand at a CAGR of 6.1% from 2021 to 2031
The market is driven by an increase in the use of albumin to treat hypoalbuminemia in patients with chronic injuries
North America accounted for a major share of the global market, owing to an increase in demand for albumin in clinical research activities
Key players in the global market for albumin include Biotest AG, CSL Behring LLC, HiMedia Laboratories Pvt. Ltd., Grifols International, S.A., Medxbio Pte Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Albumin Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Albumin Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Key Industry Events (mergers, acquisitions, partnerships, etc.)
5.2. Regulatory Scenario by Key Countries
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Albumin Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Human Serum Albumin
6.3.2. Recombinant Albumin
6.4. Market Attractiveness Analysis, by Product
7. Global Albumin Market Analysis and Forecasts, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Human Serum Albumin Applications
7.3.1.1. Drug Formulation
7.3.1.2. Drug Delivery
7.3.1.3. Vaccines
7.3.1.4. Medical Device Coating
7.3.1.5. Culture Media & Stabilizers
7.3.1.6. Diagnostics
7.3.1.7. In Vitro Fertilization
7.3.2. Recombinant Albumin Applications
7.3.2.1. Drug Formulation
7.3.2.2. Drug Delivery
7.3.2.3. Vaccines
7.3.2.4. Medical Device Coating
7.3.2.5. Culture Media & Stabilizers
7.3.2.6. Diagnostics
7.3.2.7. In Vitro Fertilization
8. Global Albumin Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Pharmaceutical & Biotechnology Companies
8.3.2. Research Institutes
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Albumin Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Albumin Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2017–2031
10.2.1. Human Serum Albumin
10.2.2. Recombinant Albumin
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Human Serum Albumin Applications
10.3.1.1. Drug Formulation
10.3.1.2. Drug Delivery
10.3.1.3. Vaccines
10.3.1.4. Medical Device Coating
10.3.1.5. Culture Media & Stabilizers
10.3.1.6. Diagnostics
10.3.1.7. In Vitro Fertilization
10.3.2. Recombinant Albumin Applications
10.3.2.1. Drug Formulation
10.3.2.2. Drug Delivery
10.3.2.3. Vaccines
10.3.2.4. Medical Device Coating
10.3.2.5. Culture Media & Stabilizers
10.3.2.6. Diagnostics
10.3.2.7. In Vitro Fertilization
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Pharmaceutical & Biotechnology Companies
10.4.2. Research Institutes
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Albumin Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Human Serum Albumin
11.2.2. Recombinant Albumin
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Human Serum Albumin Applications
11.3.1.1. Drug Formulation
11.3.1.2. Drug Delivery
11.3.1.3. Vaccines
11.3.1.4. Medical Device Coating
11.3.1.5. Culture Media & Stabilizers
11.3.1.6. Diagnostics
11.3.1.7. In Vitro Fertilization
11.3.2. Recombinant Albumin Applications
11.3.2.1. Drug Formulation
11.3.2.2. Drug Delivery
11.3.2.3. Vaccines
11.3.2.4. Medical Device Coating
11.3.2.5. Culture Media & Stabilizers
11.3.2.6. Diagnostics
11.3.2.7. In Vitro Fertilization
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Pharmaceutical & Biotechnology Companies
11.4.2. Research Institutes
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Asia Pacific Albumin Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Human Serum Albumin
12.2.2. Recombinant Albumin
12.3. Market Value Forecast by Application, 2017–2031
12.3.1. Human Serum Albumin Applications
12.3.1.1. Drug Formulation
12.3.1.2. Drug Delivery
12.3.1.3. Vaccines
12.3.1.4. Medical Device Coating
12.3.1.5. Culture Media & Stabilizers
12.3.1.6. Diagnostics
12.3.1.7. In Vitro Fertilization
12.3.2. Recombinant Albumin Applications
12.3.2.1. Drug Formulation
12.3.2.2. Drug Delivery
12.3.2.3. Vaccines
12.3.2.4. Medical Device Coating
12.3.2.5. Culture Media & Stabilizers
12.3.2.6. Diagnostics
12.3.2.7. In Vitro Fertilization
12.4. Market Value Forecast, by Product, 2017–2031
12.4.1. Pharmaceutical & Biotechnology Companies
12.4.2. Research Institutes
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. South Korea
12.5.4. India
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Albumin Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Human Serum Albumin
13.2.2. Recombinant Albumin
13.3. Market Value Forecast by Application, 2017–2031
13.3.1. Human Serum Albumin Applications
13.3.1.1. Drug Formulation
13.3.1.2. Drug Delivery
13.3.1.3. Vaccines
13.3.1.4. Medical Device Coating
13.3.1.5. Culture Media & Stabilizers
13.3.1.6. Diagnostics
13.3.1.7. In Vitro Fertilization
13.3.2. Recombinant Albumin Applications
13.3.2.1. Drug Formulation
13.3.3. Drug Delivery
13.3.3.1. Vaccines
13.3.3.2. Medical Device Coating
13.3.3.3. Culture Media & Stabilizers
13.3.3.4. Diagnostics
13.3.3.5. In Vitro Fertilization
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Pharmaceutical & Biotechnology Companies
13.4.2. Research Institutes
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Albumin Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2031
14.2.1. Human Serum Albumin
14.2.2. Recombinant Albumin
14.3. Market Value Forecast, by End-user, 2017–2031
14.3.1. Pharmaceutical & Biotechnology Companies
14.3.2. Research Institutes
14.3.3. Others
14.4. Market Value Forecast, by Country/Sub-region, 2017–2031
14.4.1. GCC Countries
14.4.2. South Africa
14.4.3. Rest of Middle East & Africa
14.5. Market Attractiveness Analysis
14.5.1. By Product
14.5.2. By Application
14.5.3. By End-user
14.5.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2020
15.3. Company Profiles
15.3.1. Albumedix A/S
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Analysis
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Albumin Therapeutics, LLC
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Analysis
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. Biotest AG
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Analysis
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. CSL Behring LLC
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Analysis
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. Grifols International, S.A.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Analysis
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. HiMedia Laboratories Pvt. Ltd.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Analysis
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. InVitria
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Analysis
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Medxbio Pte Ltd.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Financial Analysis
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Octapharma AG
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Financial Analysis
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
15.3.10. RayBiotech, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Financial Analysis
15.3.10.3. Growth Strategies
15.3.10.4. SWOT Analysis
15.3.11. Seracare Life Sciences (LGC)
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Financial Analysis
15.3.11.3. Growth Strategies
15.3.11.4. SWOT Analysis
15.3.11.5. SWOT Analysis
15.3.12. Sigma-Aldrich Co. (Merck KGaA)
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Financial Analysis
15.3.12.3. Growth Strategies
15.3.12.4. SWOT Analysis
15.3.13. Takeda Pharmaceutical Company Limited (Shire)
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Financial Analysis
15.3.13.3. Growth Strategies
15.3.13.4. SWOT Analysis
List of Tables
Table 01: Global Albumin Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 02: Global Albumin Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Albumin Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications,2017–2031
Table 04: Global Albumin Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 05: Global Albumin Market Value (US$ Mn), Forecast, 2017–2031
Table 06: Global Albumin Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Albumin Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 08: North America Albumin Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 09: North America Albumin Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 10: North America Albumin Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications,2017–2031
Table 11: North America Albumin Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 12: North America Albumin Market Value (US$ Mn), Forecast, by End-user, 2017–2031
Table 13: Europe Albumin Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 14: Europe Albumin Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 15: Europe Albumin Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 16: Europe Albumin Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications,2017–2031
Table 17: Europe Albumin Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 18: Europe Albumin Market Value (US$ Mn), Forecast, by End-user, 2017–2031
Table 19: Asia Pacific Albumin Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 20: Asia Pacific Albumin Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 21: Asia Pacific Albumin Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 22: Asia Pacific Albumin Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications,2017–2031
Table 23: Asia Pacific Albumin Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 24: Asia Pacific Albumin Market Value (US$ Mn), Forecast, 2017–2031
Table 25: Latin America Albumin Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 26: Latin America Albumin Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 27: Latin America Albumin Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 28: Latin America Albumin Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications,2017–2031
Table 29: Latin America Albumin Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 30: Latin America Albumin Market Value (US$ Mn), Forecast, 2017–2031
Table 31: Middle East & Africa Albumin Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 32: Middle East & Africa Albumin Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 33: Middle East & Africa Albumin Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 34: Middle East & Africa Albumin Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications,2017–2031
Table 35: Middle East & Africa Albumin Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 36: Middle East & Africa Albumin Market Value (US$ Mn), Forecast, 2017–2031
List of Figures
Figure 01: Global Albumin market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Albumin market Value Share, by Product Type, 2020
Figure 03: Global Albumin market Value Share, by End-user, 2020
Figure 04: Global Albumin market Value Share, by Region, 2020
Figure 05: Global Albumin Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 06: Global Albumin Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 07: Global Albumin Market Revenue (US$ Mn), by Human Serum Albumin, 2017–2031
Figure 08: Global Albumin Market Revenue (US$ Mn), by Recombinant Albumin, 2017–2031
Figure 09: Global Albumin Market Value Share Analysis, by Application, 2020 and 2031
Figure 10: Global Albumin Market Attractiveness Analysis, by Application, 2021–2031
Figure 11: Global Albumin Market Revenue (US$ Mn), by Human Serum Albumin Applications, 2017–2031
Figure 12: Global Albumin Market Revenue (US$ Mn), by Recombinant Albumin Applications, 2017–2031
Figure 13: Global Albumin Market, by End-user, 2020 and 2031
Figure 14: Global Albumin Market, by End-user, 2021–2031
Figure 15: Global Albumin Market (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017–2031
Figure 16: Global Albumin Market (US$ Mn), by Research Institutes, 2017–2031
Figure 17: Global Albumin Market (US$ Mn), by Others, 2017–2031
Figure 18: Global Albumin Market Value Share Analysis, by Region, 2020 and 2031
Figure 19: Global Albumin Market Attractiveness Analysis, by Region, 2021–2031
Figure 20: North America Albumin Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 21: North America Albumin Market Value Share Analysis, by Country, 2020 and 2031
Figure 22: North America Albumin Market Attractiveness Analysis, by Country, 2021–2031
Figure 23: North America Albumin Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 24: North America Albumin Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 25: North America Albumin Market Value Share Analysis, by Application, 2020 and 2031
Figure 26: North America Albumin Market Attractiveness Analysis, by Application, 2021–2031
Figure 27: North America Albumin Market, by End-user, 2020 and 2031
Figure 28: North America Albumin Market, by End-user, 2021–2031
Figure 29: Europe Albumin Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031
Figure 30: Europe Albumin Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 31: Europe Albumin Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 32: Europe Albumin Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 33: Europe Albumin Market Value Share Analysis, by Application, 2020 and 2031
Figure 34: Europe Albumin Market Attractiveness Analysis, by Application, 2021–2031
Figure 35: Europe Albumin Market, by End-user, 2020 and 2031
Figure 36: Europe Albumin Market, by End-user, 2021–2031
Figure 37: Asia Pacific Albumin Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031
Figure 38: Asia Pacific Albumin Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 39: Asia Pacific Albumin Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 40: Asia Pacific Albumin Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 41: Asia Pacific Albumin Market Value Share Analysis, by Application, 2020 and 2031
Figure 42: Asia Pacific Albumin Market Attractiveness Analysis, by Application, 2021–2031
Figure 43: Asia Pacific Albumin Market, by End-user, 2020 and 2031
Figure 44: Asia Pacific Albumin Market, by End-user, 2021–2031
Figure 45: Latin America Albumin Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031
Figure 46: Latin America Albumin Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 47: Latin America Albumin Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 48: Latin America Albumin Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 49: Latin America Albumin Market Value Share Analysis, by Application, 2020 and 2031
Figure 50: Latin America Albumin Market Attractiveness Analysis, by Application, 2021–2031
Figure 51: Latin America Albumin Market, by End-user, 2020 and 2031
Figure 52: Latin America Albumin Market, by End-user, 2021–2031
Figure 53: Middle East & Africa Albumin Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 54: Middle East & Africa Albumin Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031
Figure 55: Middle East & Africa Albumin Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 56: Middle East & Africa Albumin Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 57: Middle East & Africa Albumin Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 58: Middle East & Africa Albumin Market Value Share Analysis, by Application, 2020 and 2031
Figure 59: Middle East & Africa Albumin Market Attractiveness Analysis, by Application, 2021–2031
Figure 60: Middle East & Africa Albumin Market, by End-user, 2020 and 2031
Figure 61: Middle East & Africa Albumin Market, by End-user, 2021–2031
Figure 62: Global Albumin Market Share, by Company, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Albumin Market
